Re: Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

European Urology

Volumn 58, Issue 4, 2010, Pages 632-633

  Schenk, Ellen A M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PROSTATE SPECIFIC ANTIGEN;

ANTIGEN EXPRESSION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CASTRATION; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSURVEILLANCE; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; TUMOR GROWTH;

EID: 77956515957     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2010.07.016     Document Type: Note

References (3)

1. A. Hamaï, H. Benlalam, and F. Meslin Immune surveillance of human cancer: if the cytotoxic T-lymphocytes play the music, does the tumoral system call the tune? Tissue Antigens 75 2010 1 8
2. FDA approves a cellular immunotherapy for men with advanced prostate cancer. US Food and Drug Administration Web site. www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm210174.htm.
3. J.L. Gulley, P.M. Arlen, and R.A. Madan Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer Cancer Immunol Immunother 59 2010 663 674